Korean Drug Co., Ltd. (KOSDAQ:014570)
South Korea · Delayed Price · Currency is KRW 3,420.00
+15.00 (0.44%)
At close: Aug 24, 2026
Korean Drug Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 65,390 | 62,509 | 73,001 | 81,375 | 79,984 | 74,466 |
Other Revenue | -0 | -0 | - | -0 | -0 | -0 |
| 65,390 | 62,509 | 73,001 | 81,375 | 79,984 | 74,466 | |
Revenue Growth | 4.22% | -14.37% | -10.29% | 1.74% | 7.41% | 11.49% |
Cost of Revenue | 36,589 | 35,908 | 38,600 | 44,025 | 45,467 | 43,400 |
Gross Profit | 28,801 | 26,601 | 34,401 | 37,350 | 34,517 | 31,065 |
Selling, General & Admin | 20,255 | 18,874 | 24,137 | 18,136 | 19,111 | 18,529 |
Amortization of Goodwill & Intangibles | 16.74 | 18.41 | 169.6 | 197.35 | 156.68 | 248.27 |
Other Operating Expenses | 509.45 | 494.93 | 677.64 | 724.2 | 662 | 745.93 |
Operating Expenses | 21,099 | 19,687 | 30,296 | 30,630 | 20,188 | 19,799 |
Operating Income | 7,702 | 6,913 | 4,105 | 6,720 | 14,329 | 11,266 |
Interest Expense | -4.25 | -3.88 | -4.24 | -3.02 | -2.1 | -1.53 |
Interest & Investment Income | 737.86 | 657.64 | 594.69 | 1,213 | 621.01 | 133.66 |
Currency Exchange Gain (Loss) | 3.54 | -4.08 | 3.48 | 1.55 | 84.73 | 98.22 |
Other Non Operating Income (Expenses) | 409.36 | 414.91 | 218.47 | 205.88 | 32.88 | 182.37 |
EBT Excluding Unusual Items | 8,848 | 7,978 | 4,917 | 8,137 | 15,066 | 11,679 |
Gain (Loss) on Sale of Investments | -97.2 | -180.6 | 72.9 | 132.87 | -383.6 | -359.46 |
Gain (Loss) on Sale of Assets | - | 0.31 | 3.56 | -4.78 | 2.81 | 1.13 |
Pretax Income | 8,751 | 7,797 | 4,994 | 8,265 | 14,685 | 11,321 |
Income Tax Expense | 7,269 | 1,285 | 1,998 | 13,182 | 2,876 | 2,278 |
Net Income | 1,482 | 6,512 | 2,995 | -4,917 | 11,809 | 9,042 |
Net Income to Common | 1,482 | 6,512 | 2,995 | -4,917 | 11,809 | 9,042 |
Net Income Growth | -58.26% | 117.42% | - | - | 30.59% | 22.86% |
Shares Outstanding (Basic) | - | 11 | 11 | 11 | 11 | 11 |
Shares Outstanding (Diluted) | - | 11 | 11 | 11 | 11 | 11 |
Shares Change | - | 0.25% | 0.08% | -0.01% | -1.30% | 0.56% |
EPS (Basic) | - | 601.97 | 277.55 | -455.98 | 1095.09 | 827.64 |
EPS (Diluted) | - | 601.97 | 277.55 | -455.98 | 1095.09 | 827.64 |
EPS Growth | - | 116.89% | - | - | 32.31% | 22.18% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 12,960 | 12,653 | 3,842 | -2,119 | -180.15 | 7,660 |
Free Cash Flow Per Share | - | 1169.63 | 356.01 | -196.53 | -16.71 | 701.12 |
Gross Margin | 44.05% | 42.55% | 47.12% | 45.90% | 43.16% | 41.72% |
Operating Margin | 11.78% | 11.06% | 5.62% | 8.26% | 17.91% | 15.13% |
Profit Margin | 2.27% | 10.42% | 4.10% | -6.04% | 14.76% | 12.14% |
Free Cash Flow Margin | 19.82% | 20.24% | 5.26% | -2.60% | -0.22% | 10.29% |
EBITDA | 9,684 | 8,882 | 6,174 | 8,469 | 15,712 | 12,736 |
EBITDA Margin | 14.81% | 14.21% | 8.46% | 10.41% | 19.64% | 17.10% |
D&A For EBITDA | 1,982 | 1,969 | 2,069 | 1,749 | 1,383 | 1,470 |
EBIT | 7,702 | 6,913 | 4,105 | 6,720 | 14,329 | 11,266 |
EBIT Margin | 11.78% | 11.06% | 5.62% | 8.26% | 17.91% | 15.13% |
Effective Tax Rate | 83.07% | 16.48% | 40.02% | 159.49% | 19.58% | 20.13% |
Advertising Expenses | - | 105.78 | 900.89 | 920.23 | 1,014 | 1,082 |